智通财经APP获悉，先声药业(02096)早盘涨超5%，截至发稿，涨4.27%，报12.69港元，成交额4017.4万港元。
消息面上，先声药业将于8月21日召开2026年中期业绩发布会。先声药业盈喜公告显示，预计上半年收入将达45.5亿元至46.1亿元，同比增长约26.9%至28.6%；归母利润预计为8.1亿元至8.6亿元，同比增长约约34.8%至43.1%；经调整归母净利润预计为9.5亿元至10亿元，同比增长约46.5%至54.2%。主要归因于创新药收入和对外授权许可收入的增加。
华泰证券认为，在二季度行业波动大背景下，公司取得超预期水准的业绩表现，展现了新品种的强烈市场需求和高管变动后带来的效率提升，此外BD的常态化亦有望带来持续新增量。预计公司全年内生业务维持中报预告趋势，同时利润端受益BD继续跨越式提升。维持“买入”。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.